David Malcom Rodman, Chief Medical Officer at Mineralys Therapeutics, Inc. (MLYS), sold 22,734 shares at $35.90 ($819K) on 2025-09-15, disclosed to the SEC on 2025-09-16.
Scheduled sale ($819k) by Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $35.90 | 9,302 | $334K | 40.8% |
| 2 | $35.90 | 9,302 | $334K | 40.8% |
| 3 | $36.47 | 2,065 | $75K | 9.2% |
| 4 | $36.47 | 2,065 | $75K | 9.2% |
| Total | $36.00 avg | 22,734 | $819K | 100% |
| Filing → |
| MLYS | SELL | 2026-07-15 | $557K | — | Filing → |
| MLYS | SELL | 2026-07-10 | $66K | — | Filing → |
| MLYS | SELL | 2026-06-17 | $350K | — | Filing → |